Eli Lilly and Evidation Health announced that they have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation’s Andromeda data platform. As a result of this announcement, Lilly scientists and researchers across therapeutic portfolios will have access to Evidation’s data platform with the goal of uncovering new ways to measure and understand a patient’s health by accessing consented data derived from smartphones, connected sensors, wearables, and even his or her own voice. The terms of the agreement are undisclosed. With Andromeda, Lilly scientists now have access to a private, collaborative and secure analytical environment where they can use, Evidation-built algorithms to process raw data for use in clinical studies or to create their own predictive models.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.